# Manus Neurodynamica

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/manus-neurodynamica

- Industry: Medical Devices & Equipment
- Headquarters: Edinburgh, UK
- Website: www.manusneuro.com
- Total disclosed funding: $1.8M
- Latest round: Seed (May 27, 2020)
- Investors on record: 3

## About

Based in the UK, Manus Neurodynamica Ltd develops innovative medical technology solutions, notably the NeuroMotor Pen™, to assist healthcare providers in diagnosing and monitoring neuromotor impairments such as Parkinson's disease.Manus Neurodynamica Ltd specializes in creating medical devices for assessing neuromotor conditions. Founded in 2008 and headquartered in Edinburgh, UK, the company has successfully completed five funding rounds. The most recent funding, amounting to GBP 2.622 mn, came from several investors including the European Regional Development Fund, and was finalized on April 17, 2023. The current company valuation stands at GBP 6.682 mn.Manus Neurodynamica specializes in the development of the NeuroMotor Pen™, a non-invasive, patented medical device designed to aid in the diagnosis and monitoring of neuromotor impairments, particularly Parkinson's disease and tremor disorders. The NeuroMotor Pen™ employs advanced sensor technologies and analytical software to evaluate fine motor skills through standardized handwriting and drawing tasks performed by patients on a high-end tablet. This technology quantifies limb and hand motion parameters, providing clinicians with clinically validated biomarkers that offer objective insights into movement abnormalities. The primary customers of Manus Neurodynamica include healthcare providers and specialists in neurology, general practitioners, and community health organizations across Europe. The product is strategically positioned in primary care and community settings, facilitating earlier and more accurate assessments for patients exhibiting signs of neuromotor conditions.Manus Neurodynamica generates revenue primarily through direct sales of the NeuroMotor Pen™ to healthcare providers, which may involve partnerships with medical institutions and general practitioners. The company operates on a business-to-business model, providing its devices and associated software solutions to clinics and hospitals that manage patients with neuromotor disorders. The transactions typically encompass both the sale of the device and subscriptions for ongoing software support and data analytics services. This dual revenue stream enables clinicians to leverage the NeuroMotor Pen™ for differential diagnosis and treatment optimization. Specific pricing structures and revenue figures are proprietary, reflecting the advanced capabilities and unique positioning of the NeuroMotor Pen™ within the medical technology landscape.In April 2023, Manus Neurodynamica Ltd received grant funding from Johnson & Johnson Innovation. The company plans to utilize this funding to enhance the application of the NeuroMotor Pen™ within the field of immunotherapy. Future initiatives include the development of new products aimed at improving patient diagnostics and expanding their reach into additional European healthcare markets.

## Funding rounds

- Seed, May 27, 2020, $0.9M — PXN Group, Old College Capital, Scottish Enterprise
- Seed, Oct 25, 2018, $0.9M — PXN Group

## Investors

- PXN Group (https://capitalatlas.ai/funds/pxn-group) — Seed
- Old College Capital (https://capitalatlas.ai/funds/old-college-capital) — Seed
- Scottish Enterprise (https://capitalatlas.ai/funds/scottish-enterprise) — Seed